Patents by Inventor William T. Windsor

William T. Windsor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kinase domain polypeptide of human protein kinase B gamma (AKT3)
    Patent number: 8088611
    Abstract: The present invention provides, in part, AKT3 polypeptides and methods of use thereof along with nucleic acids encoding the polypeptides. For example, methods for screening for AKT3 inhibitors are provided herein.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: January 3, 2012
    Assignee: Schering Corp.
    Inventors: Andrew J. Prongay, Thierry O. Fischmann, Chandra C. Kumar, Vincent S. Madison, Joseph E. Myers, Paul Reichert, Rosalinda Syto, William T. Windsor, Li Xiao, Todd W. Mayhood
  • Polynucleotides encoding soluble, stable forms of human double minute 2 polypeptides
    Patent number: 8034907
    Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: October 11, 2011
    Assignee: Schering Corp.
    Inventors: Shahriar Shane Taremi, Gaolian Xie, Thomas Hesson, Jose S. Duca, Corey Strickland, William T. Windsor, Vincent S. Madison, Rumin Zhang, Paul Reichert, Yaolin Wang
  • BRAF BIOMARKERS
    Publication number: 20110158944
    Abstract: The present invention provides, inter alia, methods for predicting the sensitivity of a disease, such as cancer, to an ERK1 or ERK2 or MEK inhibitor by detecting the presence of an allele of BRAF in cells mediating the disease. Methods of treatment are also provided.
    Type: Application
    Filed: November 26, 2008
    Publication date: June 30, 2011
    Inventors: Thomas J. Hosted, Jason S. Simon, Marc M. Delorenzo, Donna Marie Carr, William T. Windsor, Ahmed A. Samatar
  • AKT3 POLYPEPTIDES
    Publication number: 20100267053
    Abstract: The present invention provides, in part, AKT3 polypeptides and methods of use thereof along with nucleic acids encoding the polypeptides. For example, methods for screening for AKT3 inhibitors are provided herein.
    Type: Application
    Filed: May 21, 2010
    Publication date: October 21, 2010
    Applicant: Schering Corporation
    Inventors: ANDREW J. PRONGAY, Thierry O. Fischmann, Chandra Kumar, Vincent S. Madison, Joseph E. Myers, Paul Reichert, Rosalinda Syto, William T. Windsor, Li Xiao, Todd W. Mayhood
  • Polynucleotides encoding polypeptide fragments of protein kinase B gamma (AKT3)
    Patent number: 7776589
    Abstract: The present invention provides, in part, AKT3 polypeptides and methods of use thereof along with nucleic acids encoding the polypeptides. For example, methods for screening for AKT3 inhibitors are provided herein.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: August 17, 2010
    Assignee: Schering Corporation
    Inventors: Andrew J. Prongay, Thierry O. Fischmann, Chandra Kumar, Vincent S. Madison, Joseph E. Myers, Paul Reichert, Rosalinda Syto, William T. Windsor, Li Xiao, Todd W. Mayhood
  • SOLUBLE, STABLE FORM OF HDM2, CRYSTALLINE FORMS THEREOF AND METHODS OF USE THEREOF
    Publication number: 20100136620
    Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
    Type: Application
    Filed: November 18, 2009
    Publication date: June 3, 2010
    Inventors: Shahriar Shane Taremi, Gaolian Xie, Thomas Hesson, Jose S. Duca, Corey Strickland, William T. Windsor, Vincent S. Madison, Rumin Zhang, Paul Reichert, Yaolin Wang
  • Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
    Patent number: 7632920
    Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: December 15, 2009
    Assignee: Schering Corporation
    Inventors: Shahriar Shane Taremi, Gaolian Xie, Thomas Hesson, Jose S. Duca, Corey Strickland, William T. Windsor, Vincent S. Madison, Rumin Zhang, Paul Reichert, Yaolin Wang
  • High affinity quinoline-based kinase ligands
    Patent number: 7511063
    Abstract: Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
    Type: Grant
    Filed: August 16, 2006
    Date of Patent: March 31, 2009
    Assignee: Schering Corporation
    Inventors: Yongqi Deng, Patrick J. Curran, Gerald W. Shipps, Jr., Lianyun Zhao, M. Arshad Siddiqui, Janeta Popovici-Muller, Jose S. Duca, Alan W. Hruza, Thierry O. Fischmann, Vincent S. Madison, Rumin Zhang, Charles W. McNemar, Todd W. Mayhood, William T. Windsor, Emma M. Lees, David A. Parry
  • High affinity thiophene-based and furan-based kinase ligands
    Patent number: 7446195
    Abstract: Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
    Type: Grant
    Filed: August 16, 2006
    Date of Patent: November 4, 2008
    Assignee: Schering Corporation
    Inventors: Yongqi Deng, Lianyun Zhao, Gerald W. Shipps, Jr., Patrick J. Curran, M. Arshad Siddiqui, Rumin Zhang, Charles W. McNemar, Todd W. Mayhood, William T. Windsor, Emma M. Lees, David A. Parry
  • Novel high affinity quinoline-based kinase ligands
    Publication number: 20080045568
    Abstract: Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
    Type: Application
    Filed: August 16, 2006
    Publication date: February 21, 2008
    Inventors: Yongqi Deng, Patrick J. Curran, Gerald W. Shipps, Lianyun Zhao, M. Arshad Siddiqui, Janeta Popovici-Muller, Jose S. Duca, Alan W. Hruza, Thierry O. Fischmann, Vincent S. Madison, Rumin Zhang, Charles W. McNemar, Todd W. Mayhood, William T. Windsor, Emma M. Lees, David A. Parry
  • Peptide substrates of a proteolytic ADAM33 polypeptide and assays using the same
    Patent number: 7067273
    Abstract: The present invention discloses peptide substrates of a proteolytic ADAM33 polypeptide. The present invention also discloses methods of identifying additional substrates of a proteolytic ADAM33 polypeptide. Furthermore, the present invention discloses methods of identifying compounds that inhibit the proteolytic activity of a proteolytic ADAM33 polypeptide.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: June 27, 2006
    Assignee: Schering Corporation
    Inventors: Rumin Zhang, Jun Zou, Feng X. Zhu, James P. Durkin, William T. Windsor, Shelby P. Umland
  • Peptide substrates of a proteolytic ADAM33 polypeptide and assays using the same
    Publication number: 20040152869
    Abstract: The present invention discloses peptide substrates of a proteolytic ADAM33 polypeptide. The present invention also discloses methods of identifying additional substrates of a proteolytic ADAM33 polypeptide. Furthermore, the present invention discloses methods of identifying compounds that inhibit the proteolytic activity of a proteolytic ADAM33 polypeptide.
    Type: Application
    Filed: December 19, 2003
    Publication date: August 5, 2004
    Applicant: Schering Corporation
    Inventors: Rumin Zhang, Jun Zou, Feng X. Zhu, James P. Durkin, William T. Windsor, Shelby P. Umland
  • Treatment of malaria with farnesyl protein transferase inhibitors
    Publication number: 20040087592
    Abstract: Disclosed is a method of treating Malaria comprising administering an effective amount of an FPT inhibitor to a patient in need of such treatment alone or in combination with an additional antimalarial agent and/or agent for reversing antimalarial resistance.
    Type: Application
    Filed: October 21, 2003
    Publication date: May 6, 2004
    Inventors: William T. Windsor, Patricia C. Weber, James J-S. Wang, Corey O. Strickland, F. George Njoroge, Timothy J. Guzi, Viyyoor M. Girijavallabhan, Johan A. Ferreira, Jagdish A. Desai, Alan B. Cooper, Michael Gelb
  • Treatment of malaria with farnesyl protein transferase inhibitors
    Patent number: 6645966
    Abstract: Disclosed is a method of treating Malaria comprising administering an effective amount of an FPT inhibitor to a patient in need of such treatment alone or in combination with an additional antimalarial agent and/or agent for reversing antimalarial resistance. Also disclosed are novel Farnesyl Protein Transferase inhibitors.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: November 11, 2003
    Assignee: Schering Corporation
    Inventors: William T. Windsor, Patricia C. Weber, Corey O. Strickland, Michael Gelb
  • Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
    Publication number: 20030134846
    Abstract: Disclosed is a method of treating and or preventing infections of Trypanosoma brucei by administering to a patient, in need of such treatment, an effective amount of a Farnesyl Protein Transferase Inhibitor alone or in combination with an additional anti-Trypanosoma brucei agent and/or an anti-Trypanosoma brucei resistance reversing agent.
    Type: Application
    Filed: October 7, 2002
    Publication date: July 17, 2003
    Applicant: Schering Corporation
    Inventors: William T. Windsor, Patricia C. Weber, Corey Strickland, Rosalinda Syto, Viyyoor M. Girijavallabhan, James J. Kaminski, Zhuyan Guo
  • Treatment of malaria with farnesyl protein transferase inhibitors
    Publication number: 20030092705
    Abstract: Disclosed is a method of treating Malaria comprising administering an effective amount of an FPT inhibitor to a patient in need of such treatment alone or in combination with an additional antimalarial agent and/or agent for reversing antimalarial resistance.
    Type: Application
    Filed: January 18, 2002
    Publication date: May 15, 2003
    Applicant: Schering Corporation
    Inventors: William T. Windsor, Patricia C. Weber, James J-S Wang, Corey O. Strickland, F. George Njoroge, Timothy J. Guzi, Viyyoor M. Girijavallabhan, Johan A. Ferreira, Jagdish A. Desai, Alan B. Cooper, Michael Gelb
  • Crystallizable farnesyl protein transferase compositions, crystals thereby obtained, and methods for use
    Patent number: 6539309
    Abstract: The present invention relates to compositions and crystals of farnesyl protein transferase and farnesyl protein transferase in complex with substrates and inhibitors. Also disclosed are crystallization conditions for these compositions and their use for structural determination of FPT:FPP/FPP analog:peptide/inhibitor complexes.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: March 25, 2003
    Assignee: Schering Corporation
    Inventors: Corey Strickland, Zhen Wu, William T. Windsor, Patricia C. Weber
  • Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
    Patent number: 6451982
    Abstract: A monoclonal antibody is provided which specifically binds to human interleukin-5. Also provided are a hybridoma which produces the monoclonal antibody; complementary DNAs which encode the heavy and light chain variable regions of the monoclonal antibody and CDRs therefrom; humanized monoclonal antibodies; and pharmaceutical compositions comprising the monoclonal antibody or anti-idiotypic antibodies directed against it, humanized monoclonal antibodies, binding fragments, binding compositions or single-chain binding proteins derived from the antibody and a physiologically acceptable carrier.
    Type: Grant
    Filed: March 28, 2000
    Date of Patent: September 17, 2002
    Assignee: Schering Corporation
    Inventors: Chuan-Chu Chou, Nicholas J. Murgolo, John S. Abrams, Chung-Her Jenh, Mary E. Petro, Jon E. Silver, Stephen Tindall, William T. Windsor, Paul J. Zavodny
  • Monomeric lipophilic oligosaccharide antibiotic compositions
    Patent number: 6380172
    Abstract: This invention relates to pharmaceutical composition comprising a lipophilic oligosaccharide antibiotic in a substantially monomeric form.
    Type: Grant
    Filed: September 29, 1999
    Date of Patent: April 30, 2002
    Assignee: Schering Corporation
    Inventors: Patricia C. Weber, Ashit Kumar Ganguly, Paul Reichert, Charles W. McNemar, William T. Windsor, Eric W. Kaler
  • Peptide substrates for HCV NS3 protease assays
    Patent number: 6251583
    Abstract: Novel chromogenic, fluorogenic and fluorescence polarization substrates which are useful in HCV NS3 protease and inhibitor assays.
    Type: Grant
    Filed: April 8, 1999
    Date of Patent: June 26, 2001
    Assignee: Schering Corporation
    Inventors: Rumin Zhang, Bruce A. Malcolm, Brian M. Beyer, F. George Njoroge, James P. Durkin, William T. Windsor